secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001628280-25-045049
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance
----------------------------------------------------------------

- GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).
- Medical Devices up 14.8% reported, led by Diabetes Care CGM sales of $2.0B (+20.5% reported, +17.2% organic).
- FY2025 organic sales guidance reaffirmed at 7.5-8.0% ex-COVID; adjusted EPS narrowed to $5.12-$5.18 (midpoint double-digit growth).
- Adjusted operating margin improved 40bps to 23.0% of sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828025045049/0001628280-25-045049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828025045049/abt-20251015.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-045049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer